Screener
Rhythm Pharmaceuticals, Inc. RYTM Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Other income (expense), net | (1,704) | (644) |
| Interest expense | (4,583) | (5,409) |
| Interest income | 3,554 | 3,639 |
| Total other income (expense), net | (2,733) | (2,414) |
| Loss before income taxes | (55,094) | (49,418) |
| Provision for income taxes | 545 | 80 |
| Net loss | $(55,639) | $(49,498) |
| Accrued dividends on convertible preferred stock | (1,104) | (1,322) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s other income (expense)?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported other income (expense) of -$2.73M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s other income (expense) changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s other income (expense) decreased by 13.2% year-over-year, from -$2.41M to -$2.73M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s other income (expense)?
- Over 2 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s other income (expense) has grown at a -80.0% compound annual growth rate (CAGR), from $100.45M to -$4.03M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude